|
Download Clinical trials should be carried out sooner for H7N9 vaccine products, but it's not necessary to conduct large-scale public immunization, experts said. Researchers at the Shanghai Public Health Clinical Center have recently developed a genetic vaccine against H7N9 and are applying for it to undergo clinical trials. On Jan 7, Hualan Biological Engineering Inc, in Henan province, announced on its website it had finished the preclinical study of its H7N9 vaccine products and that it is waiting for the China Food and Drug Administration to approve of its application for clinical trials of the vaccine. But the CFDA has not yet approved clinical trials on any H7N9 vaccine products, said Shu Yuelong, director of the Chinese National Influenza Center. "How long it takes before we get a reply depends on where we are on the waiting list and whether the documentation we filed is fully prepared," said Liu Peicheng, an official at Sinovac Biotech Ltd in Beijing. The company announced on its website on Jan 29 that it had filed an application of clinical trials for its H7N9 vaccine products. Liu said it's possible that if H7N9 cases were to flare, the testing process would accelerate. In 2009, when human infections of H1N1 were frequently reported, the CFDA raised the priority of H1N1 vaccine product assessments, shortening waits for testing and streamlining their path to the market. | 
